Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?

Nicole DeFeudis

Editor

Nearly two months after getting the boot from the NIH’s ACTIV-3 study over a failed futility analysis, Novartis and Molecular Partners are back with mid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

No­var­tis snaps up the rights to a Covid-19 an­tivi­ral af­ter see­ing mid-stage re­sults. So where are the da­ta?

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?